

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) An aqueous formulation of a therapeutic agent comprising:

rapamycin in a pharmaceutically effective dosage;
ethanol in a residual concentration of about 1.7 1.57 percent by weight;
vitamin E TPGS in an amount of about 4.3 6.55 percent by weight; and
water in an amount of about 92 90.51 percent by weight, the
rapamycin, vitamin E TPGS and water forming a stable aqueous solution,
thereby remaining a solution without precipitation, the stable aqueous
formulation comprising a final solution of rapamycin in the range from about 4
mg/ml to about 15 mg/ml.

2. (Cancelled)

3. (Cancelled)

4. (Original) The liquid formulation according to claim 3, wherein the rapamycin comprises sirolimus.

5. (Original) The liquid formulation according to claim 3, wherein the rapamycin comprises CCI-779.

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Withdrawn) A method for the treatment of vascular disease comprising the administration of a liquid formulation of rapamycin proximate the disease site.

10. (Withdrawn) The method for the treatment of vascular disease according to claim 9, wherein the liquid formulation of rapamycin comprises rapamycin in a pharmaceutically effective dosage and one or more pharmaceutically acceptable solubility enhancers.